Contents

1. Applied Anatomy and Physiology of Pancreas 1
- Gross anatomy of pancreas 2
- Applied physiology of the pancreas 3
- Carbohydrate metabolism 6
- Glucose homeostasis 8
- Glucose homeostasis during fasting 10
- Glucose homeostasis during starvation and exercise 11
- Regulation of insulin secretion 14
- Normal insulin secretion and pattern 16
- Insulin structure and C-peptide 18
- Insulin actions 20
- Actions of other pancreatic hormones 22

2. Diabetes: Prevalence, Types, Classification, Etiopathogenesis and Pathophysiology 25
- Prevalence of diabetes mellitus—a pandemic 26
- Types of diabetes mellitus 30
- Classification of DM 32
- Etiopathogenesis of type 1 DM 34
- Type 2 diabetes mellitus 36
- Etiopathogenesis of type 2 DM 37
- Evolution of type 2 DM 41
- Pathophysiology of type 2 DM 43
- Beta cell dysfunction in type 2 DM 49
- Obesity and type 2 DM 50
- High risk abdominal obesity and adeposines 52

- Dyslipidemia in diabetes 55
- Treatment of dyslipidemia 57
- Hypertension and diabetes 58
- Metabolic syndrome (syndrome X, Reaven's syndrome) 60
- Components and treatment of metabolic syndrome 63

3. Clinical Manifestations and Diagnosis of Diabetes Mellitus 65
- Clinical manifestations of type 1 diabetes mellitus 66
- Clinical manifestations of type 2 diabetes mellitus 68
- Cutaneous manifestations of diabetes mellitus 70
- Diagnosis of diabetes mellitus 74
- Oral glucose tolerance test 78

4. Treatment Goals, Modalities and Options 81
- Treatment of diabetes mellitus 82
- Lifestyle modifications 84
- Diet in diabetics 86
- Medical nutrition in type 1 and type 2 DM 88
- Exercise in diabetes 90
- Exercise programs 91
- Oral hypoglycemic/antidiabetic drugs 94
- Insulin secretagogues—sulfonylureas (SUs) 96
- Choosing a sulfonylurea 100
- Insulin secretagogue—meglitinide derivatives 104
- Insulin sensitizers/insulin sparing drugs 106
- Biguanides—insulin sparing drugs 108
- Alpha-glucosidase inhibitors 112
- Alpha-glucosidase inhibitors—a better option for meal stimulated glucose hike 113

- Combination therapy—choosing oral agents 115
- Add-on therapy with oral hypoglycemic agents (OHA) 118
- FDA approved OHA combination therapy 120
- Insulins 122
- Insulin preparations 126
- Pharmacokinetics of insulin preparations 128
- Insulin regimens—multiple dosage 129
- Intensive insulin therapy (basal-bolus strategy) 132
- Practical guidelines for insulin therapy in type 2 DM 134
- Guidelines for insulin therapy 135
- Insulin delivery devices and injection sites 138
- Indications of insulin therapy 140
- Insulin pen and insulin pump delivery devices 142
- Insulin infusion pump therapy 143
- Insulin infusion pump device 146
- Insulin storage 147
- Insulin side effects 149
- Social and system-related barrier to insulin 151
- Oral Insulin 151
- Beyond insulin therapy 153
- Amylin deficiency and loss of its effect 155
- Amylin analog—pramlinitide 155
- Incretin and incretinomimetics 156
- GLP-1 mimetic—exenatide 158
- DPP-4 inhibition 160
- Combination therapy: Insulin plus OHA 163
- FDA approved insulin plus OHA 164
- Parameters of glycemic control 166
- Self monitoring of blood glucose 167

- Continuous glucose monitoring by sensors 169
- Glycosylated hemoglobin (HbA1c) 171
- Diabetes and sick day management 173
- Pancreatic vs Islet cell transplantation 177
- Islet cell transplantation 178
- Primary prevention of diabetes 180
- Methods to prevent type 2 DM 182
- Prevention of diabetic complications and new-onset diabetes by ACE inhibitors 184

5. Diabetic Complications and Management 189
- Diabetic ketoacidosis (DKA) 190
- Pathogenesis, clinical features and diagnosis of DKA 192
- Principles of management of DKA 194
- Hyperglycemic hyperosmolar nonketotic coma (HHNKC) 198
- Lactic acidosis 201
- Hypoglycemia in diabetes 203
- Diagnosis of hypoglycemia 205
- Etiopathogenesis of hypoglycemia 205
- Management of hypoglycemia 208
- Diabetic angiopathy 210
- Diabetic nephropathy (DN) 213
- Diabetic retinopathy 217
- Diabetic neuropathy 225
- Pathophysiology of diabetic neuropathy 226
- Neuropathic pain in diabetic neuropathy 228
- Clinical features of diabetic polyneuropathy (DPNP) 231
- Generation of pain in DPNP 233

- Diagnosis of DPNP 234
- Management of diabetic polyneuropathy 236
- Drugs to relieve diabetic neuropathic pain 238
- Choice of drug in DPNP with comorbidities 240
- Diabetic gastroparesis 242
- Management of diabetic gastroparesis 243
- Sexual dysfunction in diabetes 245
- Evaluation for erectile dysfunction 246
- Treatment for sexual dysfunction 248
- Diabetic cystopathy (autonomic bladder) 249
- Endothelial dysfunction in diabetes 251
- Mechanism of endothelial dysfunction 253
- Diabetic macroangiopathy 255
- Diabetes and atherosclerosis 256
- Risk factors and evaluation of diabetic complications 258
- Coronary atherosclerosis 260
- Thrombogenesis and diabetes 262
- Stable/unstable angina 262
- Myocardial infarction in diabetes 265
- Heart failure (HF) in diabetes 267
- Heart failure predisposes to DM 270
- Occlusive peripheral vascular disease (OPUD) 270
- Diabetic foot 272
- Pathogenesis, care and management of diabetic foot 273
- Diabetes and infection 276
- Treatment of hypertension in diabetes 277
- Treatment of dyslipidemia in diabetes 285
- Treatment of combined hyperlipidemia 287

6. Other Aspects of Diabetes 291
- Gestational DM 292
- Pregestational diabetes mellitus 292
- Management of diabetes in pregnancy 294
- Insulin therapy in DM with pregnancy 296
- Diabetic Education—a team work 296
- Curricula for diabetes self management 299
- Genetics in DM: diabetes and child's risk 301
- Diabetes and driving 305

Suggested Reading 302

Index 321